• br The SRP SR Heterodimer GTPase Tangos

  2022-02-17

  

  The SRP/SR Heterodimer: GTPase Tangos Drive Co-Translational Protein Targeting SRP and SR mediate a universally conserved protein targeting pathway responsible for the delivery of 25–30% of newly synthesized proteome to the eukaryotic endoplasmic reticulum (ER) or the bacterial plasma membrane 11

• The role of the cyclic AMP regulated exchange factor Epac

  2022-02-17

  

  The role of the cyclic AMP regulated exchange factor Epac1 is emerging in cancer (Almahariq et al., 2015, Banerjee and Cheng, 2015, Parnell et al., 2015, Parnell et al., 2015, Schmidt et al., 2013). Interestingly, in cancer cell migration, activation of Epac1 can be linked to activation of Rac. As s

• Selected GSNOR inhibitors were assessed for potential

  2022-02-17

  

  Selected GSNOR inhibitors were assessed for potential off-target activity with a panel of 54 transmembrane and soluble receptors, ion channels, and monoamine transporters. Off-target effects were estimated from the percent inhibition of receptor radio-ligand binding in the presence of 10μM of test c

• Here we demonstrate an anti inflammatory

  2022-02-17

  

  Here we demonstrate an anti-inflammatory and anticancer function for Gpr109a in colon. Gpr109a signaling imposed anti-inflammatory properties in colonic antigen-presenting cells, which in turn induced differentiation of Treg p2x receptors and IL-10-producing T cells. Gpr109a was also required for th

• br TGR agonists current developments and future landscape Th

  2022-02-17

  

  TGR5 agonists: current developments and future landscape The amphipathic nature of bile acids is crucial in aiding the digestion and nicotinic receptors of vitamins and fats. With the emerging roles of bile acids in the regulation of energy and glucose homeostasis through TGR5, the pharmaceutica

• The original Bee Synch methodology now termed Bee Synch I

  2022-02-17

  

  The original Bee Synch methodology (now termed Bee Synch I) utilizes a 5-day CIDR, GnRH (GnRH-1) and PGF on day 0, double dose of PGF on day 5, and FTAI with GnRH (GnRH-2) at 66 h after CIDR removal. Cruppe et al. (2014) reported that the inclusion of GnRH on day 0 does not contribute appreciably to

• In spite of the impressive progress made

  2022-02-17

  

  In spite of the impressive progress made in DNA glycosylase assays in recent years, few of them have clearly been viable candidates for further development and implementation in biomedical research and clinical practice. Future research efforts should be devoted to devising assays with improved perf

• Apoptosis a form of programmed cell

  2022-02-17

  

  Apoptosis, a form of programmed cell death, is a critical component in maintaining homeostasis and growth in all tissues and plays a significant role in immunity and cytotoxicity [54,55]. Although GR are expressed in all immune cells, the physiological outcomes of GR activation are highly cell type-

• The mechanism underlying the anorectic effect of OXM is

  2022-02-17

  

  The mechanism underlying the anorectic effect of OXM is well established. It is centrally mediated via GLP-1 receptor activation, confirmed by both pharmacological blockade of the GLP-1 receptor, and using GLP-1 receptor knock-out mice [2], [11], [12]. However, the mechanism by which it increases en

• br SMO antagonists pitfalls and limitations The

  2022-02-17

  

  SMO antagonists: pitfalls and limitations The first Hh inhibitor discovered was cyclopamine, a naturally occurring alkaloid isolated from Veratrum californicum[21], which inactivates SMO by directly binding to its hepathelical bundle. Nevertheless, cyclopamine has shown several limitations as a d

• The biological actions of ghrelin are mainly due

  2022-02-17

  

  The biological actions of ghrelin are mainly due to its interaction with GHSR-1a (Howard et al., 1996). The pharmacological properties of D-Lys3-GHRP-6, a selective antagonist of GHSR-1a, have been extensively studied (Beck et al., 2004, Benso et al., 2007, Sibilia et al., 2006). To study the recept

• Inhibitors against the proteasome a component of the

  2022-02-17

  

  Inhibitors against the proteasome, a component of the ubiquitin-proteasome pathway that degrades cellular proteins, provide a new strategy for targeting the 26S proteasome [25]. Proteasome inhibitors can exhibit potent anti-cancer effects against different tumor SM-164 and were shown to induce apop

• So what makes a FFAR agonist

  2022-02-16

  

  So what makes a FFAR1 agonist different and interesting? As shown in the , the cellular mechanism is different from those of present insulin-releasing pharmacotherapies—namely the secretion initiators (sulphonylureas and meglitinides) and the incretin-based secretion potentiators (glucagon-like pept

• br Author contributions br Declaration

  2022-02-16

  

  Author contributions Declaration of conflict of interest Acknowledgements We are grateful to the Director, National Institute of Immunology for his support. The work was partially supported by J.C. Bose Fellowship to SSM. We acknowledge the help from staff of Small Animal Facility of Nation

• In conclusion re evaluation of HER

  2022-02-16

  

  In conclusion, re-evaluation of HER2 status is necessary to determine the appropriate use of anti-HER2–targeted therapy beyond disease progression. EGFR and c-met amplification, as well as PIK3CA mutation, are rarely associated with acquired resistance. Our results highlight the importance of formal

1052 records 43/71 page Previous Next First page 上5页 4142434445 下5页 Last page